(Q44053509)

English

Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia

scientific article published in August 2002

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Gemfibrozil lowers plasma lipids and increases polyunsaturated fatty acid content and oxidative susceptibility of lipoproteins in hypertriglyceridemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

0 references

0 references

author name string

W Grady Smith

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jiang Wang

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

An Q Dang

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Charles Reeves

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

David Bibbs

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Fred H Faas

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

1 August 2002

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Clinica Chimica Acta

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

322

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

1-2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

77-84

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Lewis A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Feasibility of using an oleate-rich diet to reduce the susceptibility of low-density lipoprotein to oxidative modification in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: in vitro and ex vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Oxidation of low-density lipoproteins: effect of antioxidant content, fatty acid composition and intrinsic phospholipase activity on susceptibility to metal ion-induced oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Low density lipoprotein rich in oleic acid is protected against oxidative modification: implications for dietary prevention of atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

How different constituents of low density lipoprotein determine its oxidizability by copper: a correlational approach

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Safety considerations of polyunsaturated fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Antioxidant Protection of LDL by Physiological Concentrations of 17β-Estradiol

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Calcium-channel blockers inhibit human low-density lipoprotein oxidation by oxygen radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Effects of in vitro addition of captopril on copper-induced low density lipoprotein oxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Troglitazone increases the resistance of low density lipoprotein to oxidation in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Differential effects of fibrates on the acyl composition of microsomal phospholipids in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Different effects of fibrates on the microsomal fatty acid chain elongation and the acyl composition of phospholipids in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil in hyperlipidaemic patients with peripheral arterial disease: some undiscovered actions

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Effect of gemfibrozil on the composition and oxidation properties of very-low-density lipoprotein and high-density lipoprotein in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Beneficial effect of gemfibrozil on the chemical composition and oxidative susceptibility of low density lipoprotein: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil treatment potentiates oxidative resistance of high-density lipoprotein in hypertriglyceridemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Effect of gemfibrozil on fatty acids in lipid fractions of plasma from patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Simple and rapid assessment of lipoprotein susceptibility to oxidation in the macromolecule fraction of plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Lipoprotein susceptibility to oxidation in the macromolecular fraction of plasma: relation to plasma lipids and oleate/linoleate ratio in comparison with whole plasma in hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Normal oxidative stress and enhanced lipoprotein resistance to in vitro oxidation in hypertriglyceridemia: effects of bezafibrate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Methods to determine oxidation of low-density lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Altered fatty acid composition in the plasma, platelets, and aorta of the streptozotocin-induced diabetic rat

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Gemfibrozil-induced decrease in serum ubiquinone and alpha- and gamma-tocopherol levels in men with combined hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0009-8981%2802%2900129-8

7 January 2021

Identifiers

10.1016/S0009-8981(02)00129-8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44053509&oldid=2106061832"